Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2020.1767071
Abstract: ABSTRACT Introduction Due to the primary role of PD-1 and LAG-3 in regulating the immune response in tumors, there is a need to develop therapies focused on the inhibition of PD-1 and LAG-3 in order… read more here.
Keywords: anti lag; lag antibodies; treatment; lag ... See more keywords
Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3184
Abstract: Background: Tumor immunotherapy, especially the combination of PD-1/PD-L1 inhibitors and chemotherapy, has developed rapidly. However, the systemic side effects induced by chemotherapy remain a crucial problem that needs to be addressed. Antibody-drug conjugates (ADCs) are… read more here.
Keywords: cancer; mmae; cpl976 mmae; based bispecific ... See more keywords